期刊文献+

Tpr-Met转化的Ba/F3稳定株的构建 被引量:1

Construction of a recombinant stable Ba/F3 cell strain containing Tpr-Met
下载PDF
导出
摘要 目的:建立一种可用于高通量筛选c-Met抑制剂的细胞模型。方法:采用电转染将Tpr-Met表达载体导入Ba/F3细胞中并筛选出能够稳定表达Tpr-Met的细胞株。而后对这种稳定株的白细胞介素3(IL-3)非依赖性增殖、Tpr-Met的表达及下游通路的活化、c-Met抑制剂SU11274对细胞增殖和信号通路的抑制作用进行全面评价。通过酶标仪检测细胞MTS吸光度值判断细胞的增殖水平,通过Western blot法检测Tpr-Met的表达及下游通路的活化、c-Met抑制剂SU11274对细胞信号通路的抑制作用。结果:获得稳定表达Tpr-Met的Ba/F3细胞株,该细胞株呈现IL-3非依赖性生长;能够表达持续活化的Tpr-Met;下游信号通路中关键分子Erk的磷酸化水平显著提升;c-Met特异性抑制剂SU11274通过抑制Tpr-Met磷酸化抑制下游信号通路的活化并抑制稳定株细胞增殖。结论:成功构建了Tpr-Met转化的Ba/F3细胞株。 AIM: To construct a stable cell strain encoding tumor-associated fused gene which expresses oncoprotein Tpr-Met. METHODS. We transfected Tpr-Met vector into Ba/F3 cells and screened the cell strain stably expressing Tpr-Met. The interleukin 3 (IL-3) independent proliferation of the cells was measured using the MTS assay. The expression of Tpr-Met, the activity of downstream signal transduction pathway and SU1 1274-induced inhibition of the signal pathway were investigated by Western blotting. RE- SULTS: We obtained a Ba/F3 cell strain stably expressing Tpr-Met. The cells presented IL-3 independent proliferation, suggesting a malignant transformation of the cell line. In Tpr-Met transformed Ba/F3 cells, the phosphorylation of Met and ERK were enhanced; however, specific c-Met inhibitor SU11274 suppressed the cell proliferation and c-Met phosphorylation. CONCLUSION: Tpr-Met transformed Ba/ F3 strain has been successfully constructed.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2012年第11期1151-1153,1157,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家高技术研究发展计划(863)资助(2012AA020206)
关键词 Tpr-Met BA F3细胞 IL-3非依赖性生长 信号通路 Tpr-Met Ba/F3 cell IL-3 independentgrowth signal pathway
  • 相关文献

参考文献9

  • 1Yap TA,Sandhu SK,Alam SM. HGF/c-MET targeted therapeutics:novel strategies for cancer medicine[J].Curr Drag Targets,2011,(14):2045-2058.
  • 2Mak HH,Peschard P,Lin T. Oncogenic activation of the Met receptor tyrosine kinase fusion protein,Tpr-Met,involves exclusion from the endocytic degradative pathway[J].Oncogene,2007,(51):7213-7221.doi:10.1038/sj.onc.1210522.
  • 3Peschard P,Park M. From Tpr-Met to Met,tumorigenesis and tubes[J].Oncogene,2007,(09):1276-1285.doi:10.1038/sj.onc.1210201.
  • 4Soman NR,Wogan GN,Rhim JS. TPR-MET oncogenic rearrangement:detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell lines[J].Proceedings of the National Academy of Sciences(USA),1990,(02):738-742.
  • 5Warmuth M,Kim S,Gu XJ. Ba/F3 cells and their use in kinase drug discovery[J].Current Opinion in Oncology,2007,(01):55-60.doi:10.1097/CCO.0b013e328011a25f.
  • 6Inagaki Y,Qi F,Gao J. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth[J].Biosci Trends,2011,(02):52-56.
  • 7刘宏侠,杨俊泉,汪宏斌,孙玉满.非小细胞肺癌中c-Met蛋白的表达及预后意义[J].细胞与分子免疫学杂志,2010,26(10):1027-1029. 被引量:2
  • 8Tiedt R,Degenkolbe E,Furet P. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients[J].Cancer Research,2011,(15):5255-5264.
  • 9Zhang Y,Kaplan-Lefko PJ,Rex K. Identification of a novel recepteur d 'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo[J].Cancer Research,2008,(16):6680-6687.doi:10.1158/0008-5472.CAN-07-6782.

二级参考文献7

  • 1Kim ES, Salgia R. MET pathway as a therapeutic target[ J]. J Thorac Oncol, 2009, 4(4) : 444 -447.
  • 2Garcia S, Dales JP, Jacquemier J. c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays [J]. Br J Cancer, 2007, 96(2) : 329 -335.
  • 3Weidner N. Intratumor microvessel density as a prognostic factor in cancer[J]. Am J Pathol, 1995, 147( 1 ) : 9 - 19.
  • 4Welrn AL, Kim S, Welm B. MET and MYC cooperate in mammary tumorigenesis[J]. Proe Natl Acad Sci USA, 2005, 102(12) : 4324 -4329.
  • 5Sattler M, Salgia R. The MET axis as a therapeutic target[J]. Update Cancer Ther, 2009, 3(3) : 109 - 118.
  • 6Meert AP, Paesmans M, Martin B. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the hterature with meta-analysis[J]. Br J Cancer, 2002, 87(7) : 694 -701.
  • 7Mineo TC, Ambrogi V, Baldi A. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and turnout vessel invasion after radical surgery for IB-IIA non-small cell lung cancer [ J ]. J Clin Pathal, 2004, 57(6) : 591 -597.

共引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部